Iterion Therapeutics Initiates Phase 1 Clinical Study of Tegavivint in Patients with Desmoid Tumors

Iterion Therapeutics, formerly known as Beta Cat Pharmaceuticals, today announced that it has initiated a multi-center Phase 1 clinical study of Tegavivint, its lead therapeutic candidate, in patients with desmoid tumors that are unresectable and symptomatic or progressive.

The release as fetched from its publisher. iteriontherapeutics.com ↗